When GSK’s new CEO Luke Miels told investors last month that “smart business development” is a key pillar for his strategy, he wasn’t lying. | Like Merck & Co.’s PAH drug Winrevair—which brought in $1 ...

GSK is continuing to bolster its siRNA portfolio by paying $40 million upfront for a pair of oligonucleotide therapies from ...

Perched on the cliffs of Torrey Pines, investors, CEOs, and scientists this week debated whether U.S. biotechs are losing ground to China. Meanwhile, across the Pacific, Chinese companies were busy ...

Gilead Sciences will pay an 80% premium to Arcellx’s closing price Friday to acquire the cancer drug developer.

ADS Will Begin Trading Reflecting the Ratio Change on March 2, 2026 REHOVOT, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a ...

Gilead Sciences Inc. agreed to buy US biotech Arcellx Inc. in a deal with an equity value of up to $7.8 billion.

The deal builds on a 2022 collaboration between Arcellx and Kite, a Gilead company, and eliminates profit-sharing and milestone structures, consolidating economics under Gilead as it deepens its ...

As Demy-Colton and EBD Group’s Biotech Showcase™ concluded its 18th year SAN FRANCISCO, CA, UNITED STATES, February 10, ...

Agreement provides additional funding tool of up to $25 million over a period of up to 36 months - Underpins the Company's ambitions to expand its commercialisation activities and advance its innovati ...

AI is rewriting biotech’s commercial playbook—cutting waste, shrinking teams, and giving first‑time drugmakers a faster, smarter path to launch.